Natera, Inc. (NASDAQ:NTRA) Insider Sells $296,082.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $109.66, for a total transaction of $296,082.00. Following the sale, the insider now directly owns 304,508 shares in the company, valued at $33,392,347.28. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $108.30, for a total transaction of $108,300.00.
• On Thursday, April 25th, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $89.55, for a total transaction of $89,550.00.
• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The stock was sold at an average price of $92.47, for a total transaction of $2,468,949.00.
• On Thursday, March 28th, Jonathan Sheena sold 447 shares of Natera stock. The stock was sold at an average price of $90.22, for a total transaction of $40,328.34.

Natera Stock Performance

NTRA opened at $111.39 on Thursday. The firm’s 50 day moving average is $103.60 and its 200-day moving average is $85.10. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $117.23. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. The company had revenue of $367.70 million for the quarter, compared to analyst estimates of $316.31 million. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business’s quarterly revenue was up 52.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.23) earnings per share. On average, equities research analysts predict that Natera, Inc. will post -2.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NTRA. TD Cowen raised their target price on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Jefferies Financial Group started coverage on shares of Natera in a research report on Monday, June 3rd. They issued a “buy” rating and a $142.00 target price on the stock. Craig Hallum started coverage on shares of Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. The Goldman Sachs Group raised their price target on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, April 15th. Finally, StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Friday, May 17th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.19.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI increased its stake in shares of Natera by 47.8% in the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after buying an additional 174 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of Natera by 3.0% in the fourth quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after buying an additional 179 shares during the last quarter. Treasurer of the State of North Carolina increased its stake in shares of Natera by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 45,469 shares of the medical research company’s stock worth $2,012,000 after buying an additional 230 shares during the last quarter. Oliver Lagore Vanvalin Investment Group increased its stake in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after buying an additional 389 shares during the last quarter. Finally, YHB Investment Advisors Inc. bought a new stake in shares of Natera in the first quarter worth $36,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.